CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
基本信息
- 批准号:8887060
- 负责人:
- 金额:$ 2.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-06-26 至 2015-06-25
- 项目状态:已结题
- 来源:
- 关键词:Basic ScienceChemicalsChildChild health careClinical ResearchClinical TrialsClinical Trials NetworkContraceptive AgentsContraceptive methodsContractsDevelopmentDevicesDrug FormulationsFemaleFemale Contraceptive AgentsGoalsGrantGynecologicHealth educationHuman DevelopmentInstitutesLeadLeiomyomaMale Contraceptive AgentsMethodsNational Institute of Child Health and Human DevelopmentPharmaceutical PreparationsPhasePopulation ResearchProtocols documentationReproductive HealthSafetySiteSocial WelfareTestingUnited States Food and Drug AdministrationUnited States National Institutes of HealthWomanbaseclinical research siteclinical trial phase II/III/IVdrug candidateendometriosispre-clinicalresearch and developmentsynthetic peptidetreatment trial
项目摘要
The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is the lead Federal agency for the conduct of basic and clinical research to develop new contraceptives and to evaluate existing methods of contraception and reproductive health. The Center for Population Research (CPR), within NICHD, was established in 1968 by the Secretary of Health Education and Welfare, with the important goal of developing new contraceptives through the use of contracts and grants. Within CPR, the Contraception and Reproductive Health Branch (CRHB) has long supported several preclinical contraceptive testing facilities as well as
facilities for synthetic chemical and synthetic peptide formulation. To further expand their contraceptive development capabilities, in 1996 CRHB established the NICHD Contraceptive Clinical Trials Network (CCTN). The current CCTN has conducted Phase I, II, and III clinical trials of both female and male contraceptive methods. With the recompetition of the CCTN, clinical sites will perform Phase I, II, III, and Phase IV clinical trials of a wide variety of new or existing female contraceptive methods.
The purpose of this contract is to systematically evaluate the safety and efficacy of new female contraceptive drugs and devices as well as gynecologic conditions, such as endometriosis or leiomyoma, in Phase I, II, III, and IV trials.
国家卫生研究院(NIH),即尤尼斯·肯尼迪·施莱弗国家儿童健康和人类发展研究所(NICHD),是开展基础和临床研究、开发新避孕药具和评估现有避孕和生殖健康方法的联邦牵头机构。NICHD内的人口研究中心由卫生、教育和福利部长于1968年建立,其重要目标是通过使用合同和赠款开发新的避孕药具。在CPR内,避孕和生殖健康处(CRHB)长期以来一直支持几个临床前避孕测试设施以及
合成化学品和合成肽配方的设施。为了进一步扩大他们的避孕开发能力,CRHB于1996年建立了NICHD避孕临床试验网络(CCTN)。目前CCTN已经对女性和男性避孕方法进行了I、II和III期临床试验。随着CCTN的重新竞争,临床站点将对各种新的或现有的女性避孕方法进行I、II、III和IV期临床试验。
这份合同的目的是在I、II、III和IV期试验中系统地评估新型女性避孕药和装置的安全性和有效性以及妇科疾病,如子宫内膜异位症或子宫肌瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CAROLYN L WESTHOFF其他文献
CAROLYN L WESTHOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CAROLYN L WESTHOFF', 18)}}的其他基金
CCTN - PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CCTN - 丁酸左炔诺孕酮用于女性避孕的药代动力学/药效学评价
- 批准号:
10497855 - 财政年份:2018
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CCTN - 丁酸左炔诺孕酮用于女性避孕的药代动力学/药效学评价
- 批准号:
10939295 - 财政年份:2018
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
- 批准号:
9525758 - 财政年份:2017
- 资助金额:
$ 2.54万 - 项目类别:
A Prospective, Randomized Study to Compare Effects of Ulipristal Acetate with a Combined Oral Contraceptive on Breast Epithelial Cell Proliferation.
一项前瞻性随机研究,比较醋酸乌利司他与复方口服避孕药对乳腺上皮细胞增殖的影响。
- 批准号:
9006850 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
A Prospective, Randomized Study to Compare Effects of Ulipristal Acetate with a Combined Oral Contraceptive on Breast Epithelial Cell Proliferation.
一项前瞻性随机研究,比较醋酸乌利司他与复方口服避孕药对乳腺上皮细胞增殖的影响。
- 批准号:
9307756 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - EVALUATION REVERSIBLE CONTRACEPTIVE
CCTN - 避孕临床试验网络 - 评估可逆避孕药
- 批准号:
9923499 - 财政年份:2015
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - EVALUATION REVERSIBLE CONTRACEPTIVE
CCTN - 避孕临床试验网络 - 评估可逆避孕药
- 批准号:
9149743 - 财政年份:2015
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
8933135 - 财政年份:2014
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
10271385 - 财政年份:2014
- 资助金额:
$ 2.54万 - 项目类别:
CCTN - CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION: PILOT AND EFFICACY STUDY
CCTN - 女性避孕新产品的临床评价:试点和功效研究
- 批准号:
10421163 - 财政年份:2014
- 资助金额:
$ 2.54万 - 项目类别:
相似海外基金
A Personalized Digital Intervention Program to Reduce Exposure to Endocrine Disrupting Chemicals among a Child-Bearing Age Cohort
个性化数字干预计划,以减少育龄人群接触内分泌干扰化学物质的机会
- 批准号:
10699889 - 财政年份:2022
- 资助金额:
$ 2.54万 - 项目类别:
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals (EDCs) in Women of Child-Bearing Age and their Partners
个性化移动干预减少育龄妇女及其伴侣接触内分泌干扰化学物质 (EDC)
- 批准号:
10484791 - 财政年份:2022
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10469410 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10239160 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10745230 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10205624 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
9726480 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10002319 - 财政年份:2016
- 资助金额:
$ 2.54万 - 项目类别:
Endocrine Disrupting Chemicals, Thyroid Hormones, and Child Neurobehavior
内分泌干扰化学物质、甲状腺激素和儿童神经行为
- 批准号:
8887432 - 财政年份:2015
- 资助金额:
$ 2.54万 - 项目类别:
Endocrine Disrupting Chemicals, Thyroid Hormones, and Child Neurobehavior
内分泌干扰化学物质、甲状腺激素和儿童神经行为
- 批准号:
9248209 - 财政年份:2015
- 资助金额:
$ 2.54万 - 项目类别:














{{item.name}}会员




